Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies

Abstract

The CORE Diabetes Model provides an accurate representation of patient outcomes when compared to 66 studies of diabetes and its complications. Model flexibility ensures it can be used to compare diabetes management strategies in different cohorts across a variety of clinical settings.

Cost-effectiveness of insulin analogues for diabetes mellitus

“…This model, described in detail by Palmer and colleagues, 6 has been validated against published clinical and epidemiologic studies ( Figure 1). 7 Using data derived from the published literature, the model uses mathematical equations to determine the diabetes-related complications that would occur throughout a patient's life span. 6 The equations take into consideration risk factors such as age and hemoglobin A 1c levels, as well as patient characteristics, type of diabetes and history of diabetesrelated complications.…”

“…6 For type 1 and type 2 diabetes, correlation analyses produced R 2 estimates of 0.9778 and 0.8861, which demonstrate that simulations in the Center for Outcomes Research Diabetes Model 6 provide a reasonably accurate representation of patient outcomes in real-life settings. 7 We derived the clinical effects of therapy (hemoglobin A 1c , mild to moderate hypoglycemia and severe hypoglycemia), required as inputs for the model, from meta-analyses of randomized controlled trials (Table 1). [8][9][10] We compared rapidacting insulin analogues (insulin aspart and insulin lispro) with regular human insulin.…”

“…First, the ability of the Center for Outcomes Research Diabetes Model 6 to predict long-term diabetes-related complications has been validated against published clinical and epidemiologic studies. 7 Second, as recommended by the Washington Panel on Cost Effectiveness in Health and Medicine, 29,30 we obtained our estimated decrements to utility scores from a catalogue of EuroQol-5D scores for the United States population. 29,30 Third, our economic analyses adhere to the guidelines for the economic evaluation of health technologies of the Canadian Agency for Drugs and Technologies in Health.…”

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience

“…17 Studies were chosen that described a wide range of diabetic populations, treatments, product delivery settings, and resulting outcomes. Selected studies included the necessary intermediate parameters and were also chosen based on the breadth of coverage for Baseline risk factor …”

Complication Reducing Effect of the Information Technology-Based Diabetes Management System on Subjects with Type 2 Diabetes

“…5,13,19,20 The model is based on a series of submodels that simulate the micro-and macrovascular and acute metabolic complications of diabetes and one that simulates nonspecific mortality. Each submodel has a Markov-based structure using probabilities derived from published sources.…”